Jump to content
RemedySpot.com

Yahoo! - Poor results for Rigel hepatitis drug Messenger

Rate this topic

Guest guest

By Guest guest
in Health, Medicine and Natural Healing 04

 Share

Recommended Posts

Guest guest

Guest guest

Posted
Posted

Poor results for Rigel hepatitis drug

Rigel Pharmaceuticals (NASDAQ: RIGL - news) [RIGL] has revealed disappointing

results from its phase I/II clinical study of R803, a novel oral hepatitis C RNA

polymerase inhibitor. Shares fell by four percent in response to the

announcement.

Rigel Pharmaceuticals [RIGL] has revealed disappointing results from its phase

I/II clinical study of R803, a novel oral hepatitis C RNA polymerase inhibitor.

Shares fell by four percent in response to the announcement.

http://uk.biz.yahoo.com/041123/241/f76by.html

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
 Share
Go to topic listing
×
×
  • Create New...